Open Access Research Journal of
Life Sciences
Journals home page: https://oarjpublication/journals/oarjls/
ISSN: 2783-025X (Online)

OARJ OPEN ACCESS RESEARCH JOURNALS

(REVIEW ARTICLE)

Check for updates

Regenerative medicine and stem cells: A new frontier in healthcare

Anjanjyoti Deka [1], Ankita Chakraborty [1], Shiny Ahmed [2], Juganta Kumar Kalita [1], Moksood Ahmed Laskar [1] and Priyam Jyoti Das [1,*]

[1] *Faculty of Pharmaceutical Science, Assam down town University, Sankar Madhab Path, Gandhi Nagar, Panikhaiti, Guwahati, Assam, India, 781026.*
[2] *Royal School of Pharmacy, The Assam Royal Global University-NH-37, opp. Tirupati Balaji Temple, Betkuchi, Guwahati 781035, Assam, India.*

Open Access Research Journal of Life Sciences, 2025, 09(01), 032-039

Publication history: Received on 27 December 2024; revised on 26 February 2025; accepted on 01 March 2025

Article DOI: https://doi.org/10.53022/oarjls.2025.9.1.0025

Abstract

A groundbreaking development in contemporary medicine, stem-cell therapy has the potential to revolutionize the way many crippling diseases and injuries are treated. This review explores the cutting edge of stem cell-based therapies, emphasizing the unique potential of stem cells to differentiate into a wide range of phenotypes through specialized cell differentiation and regeneration. By exploring the procedures, uses, and difficulties involved in applying stem cells across several medical specialties, this study seeks to assist researchers, doctors, and stakeholders in navigating the complex field of stem-cell treatment. Massive advances in medical science have been made possible by the historical progression from fundamental contributions in the late 19th and early 20th centuries to more recent discoveries like ESC separation and iPSC discovery. The regenerative potential of stem cells extends throughout the embryonic, adult, induced pluripotent, and perinatal phases, providing previously unheard-of therapeutic prospects in the treatment of tissue damage, cancer, neurodegenerative diseases, cardiovascular conditions, spinal cord injuries, and diabetes. However, challenges including cancer, immunological rejection, and precise control of stem-cell behaviour call for thorough investigation and creative solutions. This publication offers a comprehensive overview of the successes, challenges, and future directions in stem cell-based regenerative medicine by summarizing current biotechnological developments, critical trial evaluations, and upcoming technologies. A roadmap for stem cell treatment is provided by future directions such as immune modulation tactics, precision medicine integration, gene-editing technology breakthroughs, and bioengineering synergy. The emphasis on the potential of stem-cell therapy underscores its noteworthy impact on modern medicine and suggests a future where customized regenerative therapies will treat a range of illnesses.

Keywords: Regenerative Medicine; Stem-Cell Therapy; Neurodegenerative Disorders; Immunological Rejection; Gene-Editing Technologies; Precision Medicine

1. Introduction

Regenerative medicine is a new multidisciplinary field that aims to transform the way "to improve the health and quality of life by restoring, maintaining or enhancing tissue and functions of organs." The majority of human tissues and organs do not regenerate on their own, which explains why cell therapy is currently a significant tissue and organ repair strategy. The discovery that certain cells could produce additional cells marked the beginning of SC's history in the middle of the nineteenth century. Hematopoietic SC and stromal cells were observed in the bone marrow at the start of the 20th century, which led to the discovery of SC [1,2]. In the late 1950s, Dr. Thomas carried out the first successful transplant in Cooperstown, New York. By using identical twins, one of whom had leukaemia, the transplant avoided issues like graft-versus-host disease that come with nontwin transplants. The first successful nontwin (allogeneic) transplant was not carried out until 1968. The donor in this instance was the patient's sibling. When a donor who was

* Corresponding author: Priyam Jyoti Das.

found to be a match through a Danish blood bank gave many bone marrow transplants to a young child with a genetic immunodeficiency condition in 1973, it was the first successful unrelated donor transplant to occur in New York. The Hutchinson Centre performed the first leukaemia patient's successful unrelated donor transplant in 1979. Since then, bone marrow transplantation has grown significantly in the 1990s [3,4,5].

In 1998, the first embryonic stem cell lines were identified from the inner cell mass of early embryos. The IPS (induced pluripotent stem cells) was later described by Takahashi et al. in 2006. In regenerative medicine, a variety of stem cell types, such as adult stem cells (ASC), foetal stem cells (FSC), and embryonic stem cells (ESC), can be utilized. When it comes to their potential for clinical use and their capacity to differentiate into various specialized cells, not all stem cells are equally interesting. Adult and foetal stem cells are undifferentiated cells that can be found in adult tissues or organs as well as within foetuses. They can develop into a variety of tissue cell types and have limited self-renewal. Adult stem cells cannot be cultured permanently, yet using them does not raise any ethical issues [6-12].

Table 1 Key Stem Cell Types and Their Applications in Regenerative Medicine

Stem Cell Type	Source	Differentiation Potential	Medical Applications	Challenges
Embryonic Stem Cells (ESCs)	Early-stage embryos	Pluripotent (all cell types)	Neurodegenerative diseases, spinal cord injury, diabetes, heart disease	Ethical concerns, risk of tumorigenesis
Adult Stem Cells (ASCs)	Bone marrow, adipose tissue, blood, etc.	Multipotent (limited differentiation)	Hematopoietic disorders, cartilage repair, myocardial regeneration	Limited proliferation, immune rejection
Induced Pluripotent Stem Cells (iPSCs)	Reprogrammed adult cells	Pluripotent	Personalized medicine, disease modelling, drug testing	Potential genetic instability, risk of mutations
Mesenchymal Stem Cells (MSCs)	Bone marrow, adipose tissue, umbilical cord	Multipotent (connective tissues)	Cartilage and bone repair, autoimmune diseases, graft-versus-host disease	Heterogeneity, risk of unwanted differentiation
Hematopoietic Stem Cells (HSCs)	Bone marrow, umbilical cord blood	Multipotent (blood cells)	Leukaemia treatment, anaemia, immune system disorders	Availability, donor matching, graft rejection
Perinatal Stem Cells	Umbilical cord, amniotic fluid, placenta	Multipotent	Neurological disorders, cardiovascular repair, tissue engineering	Ethical concerns, standardization issues

1.1 Regenerative Medicine

1.1.1 Advanced Healthcare in 2020

Regenerative medicine is starting to establish a new paradigm for therapeutic practice in the future. The leading edge of 21st-century healthcare is regenerative medicine, according to the U.S. Department of Health and Human Services paper "2020: A New Vision— A Future for Regenerative Medicine." More and more, patients and society anticipate that regenerative medicine will result in the restoration of damaged tissues, diseased organs, or birth defects. Regenerative medicine is recognized by the National Institutes of Health and National Academies as a highly promising core component of modern medical practice, thanks to groundbreaking success with bone marrow transplants for specific haematological disorders that are now standard of care and the latest developments in bioengineered stem cell platforms that offer limitless sources of autologous pluripotent progenitors and expand the scope of individualized diagnosis and therapy [13-17].

Health care will suffer an increase in ineffective therapies and a rising worldwide cost if regenerative medicine technology does not contribute to individualized goods and services. Regenerative medicine offers a "disruptive innovation" approach that is ideally positioned to contribute value and revolutionize healthcare by offering specialized, curative solutions for our patients' unmet needs. Its goal is the functional repair of damaged tissues, not just the reduction or moderation of symptoms [18-20]. Tissue repair may offer a long-term therapeutic benefit for a variety of ailments, from acquired, age-related illnesses to congenital diseases. Leveraging advances in stem cell biology and

transplant medicine, the rapidly evolving regenerative medicine arsenal, when used to treat cardiovascular diseases, promises substantial health benefits for people with measurable results for better patient care and a higher quality of life. However, in order to maximize potential return and guarantee the best possible implementation of regenerative medicine algorithms in practice, an integrated roadmap spanning the translational continuum of discovery-development-regulation-use is required [21].

The repair paradigm known as "R3." "Rejuvenation↔ replacement↔ regeneration" is the general principle that underpins the framework for heart healing (Fig. 1). The therapeutic repair paradigm, or "R3," emphasizes the complimentary approaches that frame the field's scope [20]. The three main parts of the repair triad—heart muscle self-renewal (called "rejuvenation"), transplantation-based organ recycling (called "replacement"), and, finally, the biogenesis of new tissue parts for de novo tissue restoration (called "regeneration")—offer synthetic or natural ways to maintain tissue homeostasis and accomplish long-term healing (Fig. 1).



Figure 1 The "R3" repair paradigm—Rejuvenation, Replacement, and Regeneration—outlines the complementary strategies for heart healing. This framework integrates self-renewal of heart muscle (rejuvenation), organ transplantation-based recycling (replacement), and the generation of new tissue components (regeneration) to support long-term tissue homeostasis and therapeutic recovery

Cardiomyocyte renewal, which is defined by the continuous recruitment of resident progenitor pools inside or outside the heart, is essential to the intrinsic mechanisms of cardiac tissue rejuvenation. Although their effectiveness varies from person to person and is hampered by factors such as patient age, illness status, comorbidities, concurrent medication, and genetic, epigenetic, or cogenetic impacts, self-repair mechanisms consistently support tissue homeostasis. Given that half of the cardiac mass may be replaced over the course of a lifetime, radioisotope decay in the human body—a byproduct of nuclear bomb testing fifty years ago—has recently provided an unparalleled opportunity to measure the birth date of individual cardiomyocytes [22-25]. The post-allogeneic transplantation self/non-self-chimerism characteristic of patients has notably validated the role of stem cells in postnatal heart development [26]. Moreover, stem cell loads rise in failing hearts, involving the derived cardiomyocytes from local and circulating progenitor pools [26,28]. While, rejuvenation restores the natural cardioprotective capacity, natural repair processes are usually insufficient to save a failing myocardial when there has been extensive damage, such as following a major infarction [29].

Similar to this, transplant medicine uses external substitutes to restore failing organ function and recycle used components, but it is constrained by the lack of available donors. Over 100,000 more patients would benefit from this life-saving treatment in the United States alone, where an estimated 2,500 heart transplants are performed annually [30]. Because of the size of this expanding clinical demand, more and more research is being done on alternate approaches, such as mechanical help devices. Since the technology's main goal was to "bridge" to transplant or recovery, its effectiveness has led to other indications, such as permanent or "destination" therapy for certain patients. Though now treated with medications to slow the evolution of the disease's symptoms, these important developments do not stop the growing pandemic of refractory heart failure.

To stop the course of heart disease, an increase in healing processes would encourage the adaptive response and sufficient biogenesis of functioning tissue. Reactivation of endogenous and/or introduction of exogenous progenitor cells into the wounded heart would therefore provide a viable target to alleviate the burden of disease, extrapolating from the paradigms of natural heart rejuvenation and transplant-based organ replacement. Accordingly, the next frontier of medical therapy targeted at accomplishing structural and/or functional repair has been made visible by stem cell-based regeneration. [31-33]. The engraftment of progenitor cells that need in vivo development and differentiation to create a repair outcome inside the host environment is referred to as the regenerative strategy. By boosting local progenitor pools and promoting chimera repair of injured tissues, stem cell-based regenerative medicine techniques stand to propel the advancement of medical sciences from conventional palliation toward curative therapy.

1.2 Stem cell-based regeneration.

Stem cells are a unique class of drugs made by biological processes and are categorized as "biologics." Unlike conventional medications, the active component of regenerative cytotherapy products is live cells. In a clinical trial setting, stem cell treatment has been administered to more than 3,000 ischemic heart disease patients worldwide. Meta-analyses highlight the safety and viability of stem cell-based treatment and indicate a slight but variable improvement in recovery's functional characteristics. First-generation goods, such as naïve mesenchymal stem cells extracted from the patient's bone marrow, are used in these early trials. These products are made of purified, natural human cells, usually in their native state. To determine the clinical scope and maximize the benefit of cell-based therapy in the management of cardiovascular disease, efforts are being made to continuously optimize and identify the most suitable cell source and cell type, ways to improve safety and effectiveness, the patient populations most amenable to cell-based therapy, the best time to intervene, and the most advantageous route of administration. Beyond the initial safety and feasibility problems, it is crucial to determine the functional and structural efficacy profiles of particular stem cell-based treatments in order to promote a deliberate use in future practice. Note that the majority of clinical trials conducted thus far have examined diverse cell types with varying degrees of success [34-40].

Selecting the most valuable stem cell cytotypes and guiding the logical design of next-generation clinical trials depend heavily on head-to-head comparisons between stem cell platforms, as demonstrated in this issue of the Journal with the meticulous characterization of distinct adult progenitor populations. High stringency parameters of differentiation potential and repair outcome are used in these well-designed, prototypic investigations, which are blinded, randomized, and clinically relevant. According to Armiña´n et al., intramyocardial transplantation of human mesenchymal stem cells and CD34 hematopoietic cell progenitors—derived from bone marrow and umbilical cord blood, respectively—improves left ventricular function and promotes neoangiogenesis and cell proliferation in the healing infarcted myocardium. Mesenchymal stem cells were demonstrated to be superior in lowering infarct size and avoiding ventricular remodeling in this illness model in naked rodents at an equipotent dose with respect to benefit on fractional shortening. Mesenchymal stem cells' ability to move from the injection site to the infarcted zone and their further capacity to decrease collagen deposition were proposed as factors that contributed to the positive outcome [40-41].

Using an intracoronary infusion of specific porcine progenitor populations in a large animal model of acute myocardial infarction, Dubois et al. report that autologous late-outgrowth endothelial progenitor cells are more effective than their naïve allogeneic mesenchymal stem cell counterparts in improving myocardial remodeling, favoring greater vascular density. A higher neovascularization potential of autologous late-outgrowth endothelial progenitor cells that can secrete placental growth factor, a member of the vascular endothelial growth factor family and a crucial molecule in angiogenesis and vasculogenesis, was suggested by the pro-angiogenic and paracrine matrix-modulating effects that were deduced from the gene expression and protein release profiles of cultured progenitor cell populations. According to the authors, the long-term outcome is significantly influenced by immunological condition, administration methods, and cardiomyogenic pre-specification. When taken as a whole, these studies highlight the need for ongoing progress in discovery science to improve our knowledge of stem cell biology in relation to the recipient's sick environment and cardiac healing processes. For a more effective transition from proof-of-concept studies to targeted application, these studies highlight important factors that must be taken into account, including the type of autologous versus allogeneic stem cell sources, the degree of cardiomyogenic versus vasculogenic potential, and the severity of disease-affected segments. In fact, it is expected that future scientific and clinical research in cardiovascular regenerative medicine would increasingly rely on comparative investigations. In the end, comparative effectiveness outcome analysis's rigor has the capacity to influence costs, enhance care, and inform practice [41-43].

1.3 Clinical development.

It is essential to obtain the appropriate pharmacodynamic and pharmacokinetic certifications at this point in the product development process. [33,34]. The identification of primary pharmacodymanic qualities requires appropriate biological activity markers, even if the mechanism or mechanisms of action are still not fully known. One of the most

important aspects of demonstrating overall efficacy and applicability is figuring out the ideal dosages and formulations of safe cell-based medications required to produce the intended results. Cell biodistribution, viability, and proliferation metrics after single- or multiple-dose regimens are among the pharmacokinetic factors to be taken into account. Continuous clinical trials are increasingly being planned to show sufficient efficacy in the intended patient group, show a suitable dosage schedule for the best possible therapeutic effect, and/or measure the length of the therapeutic effect for risk-benefit analysis. [38]. Clinical safety databases are therefore created to annotate adverse events, such as infection, malignant transformation, immunological response, procedural risk, and long-term safety. The next ten years will see the consideration of novel cell types—autologous or allogeneic, naïve or lineage-prespecified, natural or bioengineered—for human testing, necessitating ongoing rigor in product development. [33,44-46].

Cell-based medications use small amounts of cell samples, usually for patient-specific purposes. This presents problems with the quality-control tests that are intended for every product that is being studied. To guarantee product uniformity and traceability, cell-based pharmaceutical manufacturing must be meticulously planned and verified. Manufacturing control and management, as well as quality-control testing, are conducted in compliance with the guidelines of Good Manufacturing Practices. According to standard operating procedures, screening for karyotype stability, infectious contamination, purity, and potency—also known as release criteria—has become essential for the manufacture and banking of cells used in autologous or "off-the-shelf" allogeneic therapy. Therefore, regulatory standards for risk assessment, manufacturing quality, preclinical, and clinical research are enforced by the European Medicines Agency and the U.S. Food and Drug Administration. Cell-based medications use small amounts of cell samples, usually for patient-specific purposes. This presents problems with the quality-control tests that are intended for every product that is being studied. To guarantee product uniformity and traceability, cell-based pharmaceutical manufacturing must be meticulously planned and verified. Manufacturing control and management, as well as quality-control testing, are conducted in compliance with the guidelines of Good Manufacturing Practices. According to standard operating procedures, screening for karyotype stability, infectious contamination, purity, and potency—also known as release criteria—has become essential for the manufacture and banking of cells used in autologous or "off-the-shelf" allogeneic therapy. Therefore, regulatory standards for risk assessment, manufacturing quality, preclinical, and clinical research are enforced by the European Medicines Agency and the U.S. Food and Drug Administration [34,35].

1.4 Individualized applications.

In order to optimize therapeutic specificity, decrease treatment variability, and limit side effects, personalized medicine offers a potent tool for customizing patients' molecular profiles. [47]. There will be previously unimagined opportunities for patient-specific disease management as a result of growing understanding of the regenerative basis of cell, tissue, and organ function and their interface with the environment. These understandings will help define disease risk, identify processes mediating disease susceptibility, or target mechanism-based therapies. In order to provide predictive, individualized, and preventive solutions for customized patient-specific tactics, the developing field of regenerative medicine will therefore expand concurrently with the realization of the individualized medicine paradigm. To determine which patients may benefit from stem cell therapy, individualized treatment algorithms for regenerative medicine will need to quantify the intrinsic reparative potential. (36). Accordingly, in the new era of personalized regenerative medicine, the "stem cell load" unique to each patient will act as a "index for regenerative potential" that will be helpful for prognosis, diagnosis, prediction, and directing safe and efficient treatments at the earliest stage of illness.

2. Conclusion

This study offers physicians, researchers, and stakeholders a thorough compass for navigating the complex landscape of stem-cell therapy by compiling recent biotechnology developments, crucial trial reviews, and upcoming technologies. A roadmap for the ongoing development of stem-cell therapies is provided by future directions characterized by the integration of precision medicine, immune modulation techniques, improvements in gene-editing technologies, and collaboration with bioengineering. reflecting the ground-breaking potential of stem-cell therapy in the fields of science and medicine as well as in the lives of those who suffer from crippling illnesses and wounds. The process from conception to actual use is evidence of human creativity and the unwavering commitment to enhancing healthcare. Research on stem cells has the potential to change the medical field and usher in a new era where customized regenerative treatments can lessen the effects of a variety of illnesses.

Compliance with ethical standards

Acknowledgement

We would like to thank Assam down town University for encouraging us during the writing of this article.

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

[1] A. Islam, "Haemopoietic stem cell: a new concept," Leukemia Research, vol. 9, no. 11, pp. 1415–1432, 1985.

[2] M. Tavassoli and A. Friedenstein, "Hemopoietic stromal microenvironment," The American Journal of Hematology, vol. 15, no. 2, pp. 195–203, 1983.

[3] E. D. Thomas, H. L. Lochte Jr., J. H. Cannon, O. D. Sahler, and J. W. Ferrebee, "Supralethal whole body irradiation and isologous marrow transplantation in man," The Journal of Clinical Investigation, vol. 38, pp. 1709–1716, 1959.

[4] R. A. Gatti, H. J. Meuwissen, H. D. Allen, R. Hong, and R. A. Good, "Immunological reconstitution of sex-linked lymphopenic immunological deficiency," The Lancet, vol. 2, no. 7583, pp. 1366–1369, 1968.

[5] E. D. Thomas, "A history of haemopoietic cell transplantation," British Journal of Haematology, vol. 105, no. 2, pp. 330–339, 1999

[6] M. J. Evans and M. H. Kaufman, "Establishment in culture of pluripotential cells from mouse embryos," Nature, vol. 292, no. 5819, pp. 154–156, 1981.

[7] G. R. Martin, "Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 78, no. 12, pp. 7634– 7638, 1981.

[8] K. Takahashi and S. Yamanaka, "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors," Cell, vol. 126, no. 4, pp. 663–676, 2006.

[9] K. Takahashi, K. Tanabe, M. Ohnuki et al., "Induction of pluripotent stem cells from adult human fibroblasts by defined factors," Cell, vol. 131, no. 5, pp. 861–872, 2007.

[10] E. Galende, I. Karakikes, L. Edelmann et al., "Amniotic fluid cells are more efficiently reprogrammed to pluripotency than adult cells," Cellular Reprogramming, vol. 12, no. 2, pp. 117–125, 2010.

[11] C. Magnon, D. Lucas, and P. Frenette, "Trafficking of stem cells," in Stem Cell Migration: Methods and Protocols, vol. 750 of Methods in Molecular Biology, pp. 3–24, Humana Press, New York, NY, USA, 2011.

[12] T. Zhao, Z.-N. Zhang, Z. Rong, and Y. Xu, "Immunogenicity of induced pluripotent stem cells," Nature, vol. 474, no. 7350, pp. 212–215, 2011

[13] U.S. Department of Health and Human Services. 2020: A New Vision—A Future for Regenerative Medicine. Available at: http:// www.hhs.gov/reference/FutureofRegenerativeMedicine.pdf. Accessed April 8, 2010.

[14] Copelan E. Hematopoietic stem-cell transplantation. N Engl J Med 2006;354:1813–26.

[15] Daley GQ, Scadden DT. Prospects for stem cell-based therapy. Cell 2008;132:544 – 8

[16] National Institutes of Health. Stem Cell Information. Available at: http://stemcells.nih.gov/info/. Accessed April 8, 2010.

[17] National Academies. Stem Cells at the National Academies. Available at: http://dels.nas.edu/bls/stemcells/basics.shtml. Accessed April 8, 2010.

[18] Cortese DA. A vision of individualized medicine in the context of global health. Clin Pharmacol Ther 2007;82:491–3.

[19] Waldman SA, Terzic A. Pharmacoeconomics in the era of individualized medicine. Clin Pharmacol Ther 2008;84:179 – 82.

[20] Nelson TJ, Behfar A, Terzic A. Strategies for therapeutic repair: The "R3" regenerative medicine paradigm. Clin Transl Sci 2008;1:168 –71

[21] . Waldman SA, Terzic A. Therapeutic targeting: a crucible for individualized medicine. Clin P

[22] Anversa P, Kajstura J, Leri A, Bolli R. Life and death of cardiac stem cells: a paradigm shift in cardiac biology. Circulation 2006;113: 1451– 63.

[23] Torella D, Ellison GM, Méndez-Ferrer S, Ibanez B, Nadal-Ginard B. Resident human cardiac stem cells: role in cardiac cellular homeostasis and potential for myocardial regeneration. Nat Clin Pract Cardiovasc Med 2006;3 Suppl 1:S8 –13.

[24] Laird DJ, von Andrian UH, Wagers AJ. Stem cell trafficking in tissue development, growth, and disease. Cell 2008;132:612–30.

[25] Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science 2009;324

[26] Kajstura J, Hosoda T, Bearzi C, et al. The human heart: a self renewing organ. Clin Transl Sci 2008;1:80 – 6.

[27] Kubo H, Jaleel N, Kumarapeli A, et al. Increased cardiac myocyte progenitors in failing human hearts. Circulation 2008;118:649 –57.

[28] Rupp S, Koyanagi M, Iwasaki M, et al. Characterization of long-term endogenous cardiac repair in children after heart transplantation. Eur Heart J 2008;29:1867–72.

[29] Kajstura J, Urbanek K, Rota M, et al. Cardiac stem cells and myocardial disease. J Mol Cell Cardiol 2008;45:505–13

[30] Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009;53:e1–90.

[31] . Dimmeler S, Zeiher AM, Schneider MD. Unchain my heart: the scientific foundations of cardiac repair. J Clin Invest 2005;115:572– 83.

[32] Segers VF, Lee RT. Stem-cell therapy for cardiac disease. Nature 2008;451:937– 42.

[33] Nelson TJ, Behfar A, Yamada S, Martinez-Fernandez A, Terzic A. Stem cell platforms for regenerative medicine. Clin Transl Sci 2009; 2:222–7.

[34] European Medicines Agency. Guideline on Human Cell-Based Medicinal Products. Available at: www.emea.europa.eu/pdfs/human/ cpwp/41086906enfin.pdf. Accessed April 8, 2010.

[35] Halme DG, Kessler DA. FDA regulation of stem-cell-based therapies. N Engl J Med 2006;355:1730 –5.

[36] Nelson TJ, Behfar A, Terzic A. Stem cells: biologics for regeneration. Clin Pharmacol Ther 2008;84:620 –3.

[37] Abdel-Latif A, Bolli R, Tleyjeh IM, et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med 2007;167:989 –97.

[38] Gersh BJ, Simari RD, Behfar A, Terzic CM, Terzic A. Cardiac cell repair therapy: a clinical perspective. Mayo Clin Proc 2009;84:876 –92.

[39] Bartunek J, Sherman W, Vanderheyden M, Fernandez-Aviles F, Wijns W, Terzic A. Delivery of biologics in cardiovascular regenerative medicine. Clin Pharmacol Ther 2009;85:548 –52.

[40] Dimmeler S, Zeiher AM. Cell therapy of acute myocardial infarction: open questions. Cardiology 2009;113:155–60.

[41] Armiña´n A, Gandı´a C, Garcı´a-Verdugo JM, et al. Mesenchymal stem cells provide better results than hematopoietic precursors for the treatment of myocardial infarction. J Am Coll Cardiol 2010;55:2244 –53.

[42] Dubois C, Liu X, Claus P, et al. Differential effects of progenitor cell populations on left ventricular remodeling and myocardial neovascularization after myocardial infarction. J Am Coll Cardiol 2010;55:2232– 43.

[43] Drozda JP, Bufalino VJ, Fasules JW, et al. ACC 2009 advocacy position statement: principles for comparative effectiveness research. J Am Coll Cardiol 2009;54:1744 – 6

[44] Behfar A, Faustino RS, Arrell DK, Dzeja PP, Perez-Terzic C, Terzic A. Guided stem cell cardiopoiesis: discovery and translation. J Mol Cell Cardiol 2008;45:523–9.

[45] Nelson TJ, Martinez-Fernandez A, Yamada S, Perez-Terzic C, Ikeda Y, Terzic A. Repair of acute myocardial infarction with human stemness factors induced pluripotent stem cells. Circulation 2009;120: 408 – 6.

[46] Hansson EM, Lindsay ME, Chien KR. Regeneration next: toward heart stem cell therapeutics. Cell Stem Cell 2009;5:364 –77.

[47] Waldman SA, Terzic A. Individualized medicine and the imperative of global health. Clin Pharmacol Ther 2007;82:479 – 83.